Home
Health Care Professionals
Sitemap
Search
Diabetes care
Biopharma-
ceuticals
About Us
Health care Innovations
Partnering
Media
Careers
Contact Us
Diabetes Care
Victoza®
Levemir®
(insulin determir [rDNA origin] injection)
NovoLog®
(insulin aspart [rDNA origin] injection)
NovoLog® Mix 70/30
(70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])
Biopharmaceuticals
NovoSeven® RT
Norditropin®
(somatropin [rDNA origin] injection)
Women's Health - Hormone Therapy
Close
Your Well-Being
Helping you treat diabetes
Living with diabetes
Manage your diabetes
Loud and clear: Young Voices speak out
Your Treatment
Our products, your health
Patient Assistance
Innovations
Close
Your Well-Being
What is hemophilia with inhibitors
Support Programs
SevenSECURE®
Insurance
The Changing Possibilities Coalition
Living with hemophilia with inhibitors
Read Ashley's story
Read Alex and Adam's story
Read Robert's story
Your Treatment
Our products, your health
Close
What is Diabetes
Learning about diabetes
Guide me
What is Hemophilia with Inhibitors
Raising Awareness
Medical Screening
The Changing Possibilities Coalition
Hemophilia Support Programs
SevenSECURE®
Insurance
Working for Change
National Changing Diabetes® Program
World Diabetes
Foundation
The Novo Nordisk Hemophilia Foundation
Safe at School
Patient or caregiver
Health care professional
Career seeker
Media professional
Business partner
Follow @novonordiskus
Visit Novo Nordisk Global
May 8, 2012
Novo Nordisk Inc. Appoints Robert Clark as Vice President, Regulatory Affairs
Apr 27, 2012
Company Announcement: Operating profit increased by 18% in the first quarter of 2012